632 related articles for article (PubMed ID: 9474874)
1. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
2. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.
Lax SF; Kendall B; Tashiro H; Slebos RJ; Hedrick L
Cancer; 2000 Feb; 88(4):814-24. PubMed ID: 10679651
[TBL] [Abstract][Full Text] [Related]
3. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
Lax SF
Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
[TBL] [Abstract][Full Text] [Related]
4. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
5. Molecular carcinogenesis of endometrial cancer.
Liu FS
Taiwan J Obstet Gynecol; 2007 Mar; 46(1):26-32. PubMed ID: 17389185
[TBL] [Abstract][Full Text] [Related]
6. Theories of endometrial carcinogenesis: a multidisciplinary approach.
Sherman ME
Mod Pathol; 2000 Mar; 13(3):295-308. PubMed ID: 10757340
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis in endometrial cancer.
Caduff RF; Svoboda-Neumann SM; Johnston CM; Bartos RE; Frank TS
Verh Dtsch Ges Pathol; 1997; 81():219-27. PubMed ID: 9474873
[TBL] [Abstract][Full Text] [Related]
8. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
9. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
11. [Endometrial carcinoma and precursor lesions].
Djordjević B; Stanojević Z
Srp Arh Celok Lek; 2007; 135(3-4):230-4. PubMed ID: 17642468
[TBL] [Abstract][Full Text] [Related]
12. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
Geyer JT; López-García MA; Sánchez-Estevez C; Sarrió D; Moreno-Bueno G; Franceschetti I; Palacios J; Oliva E
Am J Surg Pathol; 2009 Aug; 33(8):1157-63. PubMed ID: 19542870
[TBL] [Abstract][Full Text] [Related]
13. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma.
Jia L; Liu Y; Yi X; Miron A; Crum CP; Kong B; Zheng W
Clin Cancer Res; 2008 Apr; 14(8):2263-9. PubMed ID: 18369088
[TBL] [Abstract][Full Text] [Related]
14. Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma.
Sakuragi N; Hirai A; Tada M; Yamada H; Yamamoto R; Fujimoto S; Moriuchi T
Gynecol Oncol; 2001 Dec; 83(3):485-90. PubMed ID: 11733960
[TBL] [Abstract][Full Text] [Related]
15. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
[TBL] [Abstract][Full Text] [Related]
16. Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma.
Cao SN; Chang KH; Luthra R; Liu J
Mod Pathol; 2003 Oct; 16(10):1048-52. PubMed ID: 14559989
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
18. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
19. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.
Schlosshauer PW; Ellenson LH; Soslow RA
Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium.
Lax SF
Pathology; 2007 Feb; 39(1):46-54. PubMed ID: 17365822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]